Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28578746 | 0.95 | JAK2 (0.41) | PIM1PPARACYP1A2GRM5JAK2 | |
| SCHEMBL13450565 | 0.79 | CYP2A6 (0.43) | PIM1PPARACYP1A2GRM5JAK2 | |
| SCHEMBL5383451 | 0.75 | TRIM24 (0.43) | PIM1PPARACYP1A2GRM5JAK2 | |
| SCHEMBL8993495 | 0.75 | PIM1 (0.37) | PIM1PPARACYP1A2GRM5JAK2 | |
| SCHEMBL13439540 | 0.75 | F2RL1 (0.40) | PIM1PPARACYP1A2GRM5JAK2 | |
| SCHEMBL8993439 | 0.75 | PIM1 (0.37) | PIM1PPARACYP1A2GRM5JAK2 | |
| SCHEMBL3083160 | 0.74 | JAK2 (0.44) | PIM1CYP1A2GRM5JAK2JAK1 | |
| SCHEMBL10094713 | 0.74 | CYP2A6 (0.42) | PIM1CYP1A2GRM5JAK2JAK1 | |
| SCHEMBL7772699 | 0.73 | CDC25B (0.46) | CYP1A2TDP1CDC25B | |
| SCHEMBL29666462 | 0.73 | CDC25B (0.46) | CYP1A2TDP1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235568-B2 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-06-26 | — | — | US | disclosed |
| US-7163957-B2 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-01-16 | — | — | US | disclosed |
| US-20060264471-A1 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derviatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2006-11-23 | — | — | US | disclosed |
| EP-1551821-B1 | 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA | PF MEDICAMENT (FR) | 2006-05-17 | — | — | EP | disclosed |
| US-20060014827-A1 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264471-A1 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derviatives and use thereof as medicines for treating schizophrenia | CNR2, CNR1, DBH | PIM1 2757/4885PPARA 1751/4885CYP1A2 89/4885 |
| US-20060014827-A1 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | CHRNA3, CHRNB3, CNR2 | PIM1 3563/4885PPARA 2406/4885CYP1A2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.